Hana Pharm Co Ltd
KRX:293480
Hana Pharm Co Ltd
Interest Income Expense
Hana Pharm Co Ltd
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hana Pharm Co Ltd
KRX:293480
|
Interest Income Expense
₩1.2B
|
CAGR 3-Years
20%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Yuhan Corp
KRX:000100
|
Interest Income Expense
₩29.4B
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-7%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Interest Income Expense
-₩24.6B
|
CAGR 3-Years
30%
|
CAGR 5-Years
-56%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Interest Income Expense
-₩9.3B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Interest Income Expense
₩9.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
17%
|
|
|
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
Interest Income Expense
-₩6.7B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-9%
|
|
Hana Pharm Co Ltd
Glance View
Hana Pharm Co., Ltd. engages in the research, development, and manufacture of pharmaceutical products. The company is headquartered in Hwaseong, Gyeonggi-Do and currently employs 657 full-time employees. The company went IPO on 2018-10-02. The company’s main products include cardiovascular drugs involves hypertension and hyperlipidemia medicines, as well as blood circulation improvement drugs; analgesics for severe pain and anesthetics for surgery and sedation; as well as gastrointestinal drugs such as peptic ulcer treatment and antispasmodics. The firm also provides antibiotics, dermatology analgesics, antipyretics and anti-inflammatory drugs.
See Also
What is Hana Pharm Co Ltd's Interest Income Expense?
Interest Income Expense
1.2B
KRW
Based on the financial report for Dec 31, 2024, Hana Pharm Co Ltd's Interest Income Expense amounts to 1.2B KRW.
What is Hana Pharm Co Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
-11%
Over the last year, the Interest Income Expense growth was 43%. The average annual Interest Income Expense growth rates for Hana Pharm Co Ltd have been 20% over the past three years , -11% over the past five years .
You don't have any saved screeners yet